Laman UtamaATHA • NASDAQ
add
Athira Pharma Inc
$0.64
Selepas Waktu Dagangan:(0.47%)-0.0030
$0.64
Tutup: 22 Nov, 7:49:03 PTG GMT-5 · USD · NASDAQ · Penafian
Tutup sebelumnya
$0.66
Julat hari
$0.63 - $0.66
Julat tahun
$0.41 - $4.30
Permodalan pasaran
24.64J USD
Bilangan Purata
9.62J
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 25.49J | -27.25% |
Pendapatan bersih | -28.74J | 12.83% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | — | — |
EBITDA | -25.25J | 27.44% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 68.86J | -60.19% |
Jumlah aset | 86.25J | -53.30% |
Jumlah liabiliti | 28.66J | -4.25% |
Jumlah ekuiti | 57.58J | — |
Syer tertunggak | 38.67J | — |
Harga kepada buku | 0.44 | — |
Pulangan pada aset | -64.54% | — |
Pulangan pada modal | -88.74% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -28.74J | 12.83% |
Tunai daripada operasi | -23.02J | 4.01% |
Tunai daripada pelaburan | 18.04J | -12.81% |
Tunai daripada pembiayaan | 12.00K | — |
Perubahan bersih dalam tunai | -4.97J | -50.94% |
Aliran tunai bebas | -10.13J | 13.86% |
Perihal
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Diasaskan
2011
Ibu pejabat
Tapak web
Pekerja
66
